FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982912497> ?p ?o ?g. }

• W1982912497 endingPage "1425" @default.
• W1982912497 startingPage "1417" @default.
• W1982912497 abstract "PURPOSE To evaluate in a prospective, multicenter setting the long-term effectiveness of polyurethane stents in the percutaneous management of epiphora. MATERIALS AND METHODS Patients (n = 426; age range, 19–88 years, mean, 48; 91 men, 335 women) with severe epiphora had stents (470 eyes/496 stents) inserted to treat unilateral or bilateral and complete or partial obstruction of the nasolacrimal system. The etiology of the obstruction was idiopathic in 280 cases (59.5%) and chronic dacryocystitis in 190 (40.4%). The stent set designed by Song was used in all patients, and the original technique was slightly modified by us and conducted on an outpatient basis. RESULTS The initial technical success rate of stent placement was 95%. The average time of the procedure was 6 minutes (range, 3–70). Resolution of epiphora was complete in 452 eyes and partial in 18. On follow-up (mean, 24 months; range, 1 week to 67 months), 340 of 496 stents remained patent (68.5%). Segregating primary patency by year of follow-up, the rates were 75.6%, 68.4%, 64.8%, 60.1%, and 59.2% in the first, second, third, fourth, and the current (67 months) years, respectively. Minor complications such as moderate pain (21 cases), epistaxis (75 cases), palpebral edema and hematoma (31 cases), and headache (four cases) and two acute dacryocystitis events were recorded. Of the 156 obstructed stents, 114 were withdrawn, and 49 of these patients remained asymptomatic for a mean of 27 months (secondary patency, 31.4%). After stent removal, the sac configuration was unchanged in 93 (81.5%), contracted in 11 (9.6%), and widened in 10 (8.8%) cases. CONCLUSIONS The procedure is simple and safe, both in stent insertion and in withdrawal when occluded. The success rate was >75% in the short term and >55% in the long term. Although not totally without concerns, the technique is attractive for most patients who prefer not to undergo surgery or are unsuitable surgical candidates. Stent failure does not preclude subsequent treatment options and is an excellent first-line treatment of epiphora. To evaluate in a prospective, multicenter setting the long-term effectiveness of polyurethane stents in the percutaneous management of epiphora. Patients (n = 426; age range, 19–88 years, mean, 48; 91 men, 335 women) with severe epiphora had stents (470 eyes/496 stents) inserted to treat unilateral or bilateral and complete or partial obstruction of the nasolacrimal system. The etiology of the obstruction was idiopathic in 280 cases (59.5%) and chronic dacryocystitis in 190 (40.4%). The stent set designed by Song was used in all patients, and the original technique was slightly modified by us and conducted on an outpatient basis. The initial technical success rate of stent placement was 95%. The average time of the procedure was 6 minutes (range, 3–70). Resolution of epiphora was complete in 452 eyes and partial in 18. On follow-up (mean, 24 months; range, 1 week to 67 months), 340 of 496 stents remained patent (68.5%). Segregating primary patency by year of follow-up, the rates were 75.6%, 68.4%, 64.8%, 60.1%, and 59.2% in the first, second, third, fourth, and the current (67 months) years, respectively. Minor complications such as moderate pain (21 cases), epistaxis (75 cases), palpebral edema and hematoma (31 cases), and headache (four cases) and two acute dacryocystitis events were recorded. Of the 156 obstructed stents, 114 were withdrawn, and 49 of these patients remained asymptomatic for a mean of 27 months (secondary patency, 31.4%). After stent removal, the sac configuration was unchanged in 93 (81.5%), contracted in 11 (9.6%), and widened in 10 (8.8%) cases. The procedure is simple and safe, both in stent insertion and in withdrawal when occluded. The success rate was >75% in the short term and >55% in the long term. Although not totally without concerns, the technique is attractive for most patients who prefer not to undergo surgery or are unsuitable surgical candidates. Stent failure does not preclude subsequent treatment options and is an excellent first-line treatment of epiphora." @default.
• W1982912497 created "2016-06-24" @default.
• W1982912497 creator A5002383569 @default.
• W1982912497 creator A5003117810 @default.
• W1982912497 creator A5024385253 @default.
• W1982912497 creator A5031720216 @default.
• W1982912497 creator A5035877208 @default.
• W1982912497 creator A5037135989 @default.
• W1982912497 creator A5047524969 @default.
• W1982912497 creator A5051991583 @default.
• W1982912497 creator A5059408277 @default.
• W1982912497 creator A5063623243 @default.
• W1982912497 creator A5087059136 @default.
• W1982912497 date "2003-11-01" @default.
• W1982912497 modified "2023-09-26" @default.
• W1982912497 title "Resolution of Epiphora with Nasolacrimal Stents: Results of Long-term Follow-up in a Multicenter Prospective Study" @default.
• W1982912497 cites W1512117647 @default.
• W1982912497 cites W1587111911 @default.
• W1982912497 cites W1921271446 @default.
• W1982912497 cites W1971002381 @default.
• W1982912497 cites W1971821685 @default.
• W1982912497 cites W1978712140 @default.
• W1982912497 cites W1982704040 @default.
• W1982912497 cites W1988690366 @default.
• W1982912497 cites W1990758475 @default.
• W1982912497 cites W2010552481 @default.
• W1982912497 cites W2016908188 @default.
• W1982912497 cites W2038041219 @default.
• W1982912497 cites W2039959164 @default.
• W1982912497 cites W2045443823 @default.
• W1982912497 cites W2045993825 @default.
• W1982912497 cites W2049518706 @default.
• W1982912497 cites W2050090938 @default.
• W1982912497 cites W2051677981 @default.
• W1982912497 cites W2057005311 @default.
• W1982912497 cites W2058940457 @default.
• W1982912497 cites W2067091120 @default.
• W1982912497 cites W2073411570 @default.
• W1982912497 cites W2075479159 @default.
• W1982912497 cites W2082035253 @default.
• W1982912497 cites W2085565268 @default.
• W1982912497 cites W2086849899 @default.
• W1982912497 cites W2093076323 @default.
• W1982912497 cites W2094301807 @default.
• W1982912497 cites W2098372488 @default.
• W1982912497 cites W2111377174 @default.
• W1982912497 cites W2121582514 @default.
• W1982912497 cites W2140292002 @default.
• W1982912497 cites W2151328253 @default.
• W1982912497 cites W2152980463 @default.
• W1982912497 cites W2163188590 @default.
• W1982912497 cites W2769752933 @default.
• W1982912497 doi "https://doi.org/10.1097/01.rvi.0000096763.74047.ef" @default.
• W1982912497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14605107" @default.
• W1982912497 hasPublicationYear "2003" @default.
• W1982912497 type Work @default.
• W1982912497 sameAs 1982912497 @default.
• W1982912497 citedByCount "24" @default.
• W1982912497 countsByYear W19829124972014 @default.
• W1982912497 countsByYear W19829124972017 @default.
• W1982912497 countsByYear W19829124972018 @default.
• W1982912497 countsByYear W19829124972019 @default.
• W1982912497 crossrefType "journal-article" @default.
• W1982912497 hasAuthorship W1982912497A5002383569 @default.
• W1982912497 hasAuthorship W1982912497A5003117810 @default.
• W1982912497 hasAuthorship W1982912497A5024385253 @default.
• W1982912497 hasAuthorship W1982912497A5031720216 @default.
• W1982912497 hasAuthorship W1982912497A5035877208 @default.
• W1982912497 hasAuthorship W1982912497A5037135989 @default.
• W1982912497 hasAuthorship W1982912497A5047524969 @default.
• W1982912497 hasAuthorship W1982912497A5051991583 @default.
• W1982912497 hasAuthorship W1982912497A5059408277 @default.
• W1982912497 hasAuthorship W1982912497A5063623243 @default.
• W1982912497 hasAuthorship W1982912497A5087059136 @default.
• W1982912497 hasConcept C141071460 @default.
• W1982912497 hasConcept C188816634 @default.
• W1982912497 hasConcept C2775942659 @default.
• W1982912497 hasConcept C2777659030 @default.
• W1982912497 hasConcept C2777910003 @default.
• W1982912497 hasConcept C2778583881 @default.
• W1982912497 hasConcept C2779190853 @default.
• W1982912497 hasConcept C2780813298 @default.
• W1982912497 hasConcept C2781296607 @default.
• W1982912497 hasConcept C71924100 @default.
• W1982912497 hasConceptScore W1982912497C141071460 @default.
• W1982912497 hasConceptScore W1982912497C188816634 @default.
• W1982912497 hasConceptScore W1982912497C2775942659 @default.
• W1982912497 hasConceptScore W1982912497C2777659030 @default.
• W1982912497 hasConceptScore W1982912497C2777910003 @default.
• W1982912497 hasConceptScore W1982912497C2778583881 @default.
• W1982912497 hasConceptScore W1982912497C2779190853 @default.
• W1982912497 hasConceptScore W1982912497C2780813298 @default.
• W1982912497 hasConceptScore W1982912497C2781296607 @default.
• W1982912497 hasConceptScore W1982912497C71924100 @default.
• W1982912497 hasIssue "11" @default.
• W1982912497 hasLocation W19829124971 @default.
• W1982912497 hasLocation W19829124972 @default.
• W1982912497 hasOpenAccess W1982912497 @default.

• next